10 Best Deeptech for October 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market environment is marked by rapid technological innovation, evolving healthcare needs, and a global push toward sustainable energy. Against this backdrop, ValueSense’s proprietary screening tools identify companies with strong fundamentals, attractive valuations, and clear growth catalysts. Our selection process emphasizes quality (measured by our proprietary Quality Rating), intrinsic value (discounted cash flow-based), revenue and free cash flow growth, and manageable debt levels. Stocks featured here span semiconductors, medical devices, renewable energy, and enterprise technology—offering a balanced mix for growth-oriented portfolios.
Featured Stock Analysis
Stock #1: ASML Holding N.V. (ASML)
| Metric | Value |
|---|---|
| Market Cap | $392.0B |
| Quality Rating | 8.0 |
| Intrinsic Value | $872.7 |
| 1Y Return | 38.8% |
| Revenue | €32.2B |
| Free Cash Flow | €9,232.7M |
| Revenue Growth | 26.4% |
| FCF margin | 28.7% |
| Gross margin | 52.5% |
| ROIC | 31.3% |
| Total Debt to Equity | 21.0% |
Investment Thesis
ASML is a cornerstone of the global semiconductor industry, providing critical lithography equipment essential for advanced chip manufacturing. With a market cap of $392.0B, ASML boasts a Quality Rating of 8.0 and an intrinsic value of $872.7. The company delivered a 38.8% one-year return, driven by 26.4% revenue growth and industry-leading margins (52.5% gross, 28.7% FCF). ASML’s return on invested capital (ROIC) stands at an impressive 31.3%, reflecting efficient capital deployment. Despite its size, ASML maintains a conservative debt profile (21.0% debt-to-equity).
Key Catalysts
- Semiconductor demand surge: Continued global chip shortages and expansion in AI, IoT, and 5G drive equipment orders.
- Technological moat: ASML’s extreme ultraviolet (EUV) lithography systems have no direct competitors.
- Global expansion: Investments in new fabs worldwide underpin multi-year growth visibility.
Risk Factors
- Cyclicality: Exposure to semiconductor industry cycles.
- Geopolitical risks: Export controls and trade tensions could impact sales.
- Concentration: A handful of customers account for a significant portion of revenue.
Stock #2: Ubiquiti Inc. (UI)
| Metric | Value |
|---|---|
| Market Cap | $45.4B |
| Quality Rating | 7.5 |
| Intrinsic Value | $155.6 |
| 1Y Return | 212.6% |
| Revenue | $2,573.5M |
| Free Cash Flow | $634.9M |
| Revenue Growth | 33.4% |
| FCF margin | 24.7% |
| Gross margin | 43.4% |
| ROIC | 85.8% |
| Total Debt to Equity | 44.5% |
Investment Thesis
Ubiquiti is a high-growth networking technology company with a $45.4B market cap, a Quality Rating of 7.5, and an intrinsic value of $155.6. The stock has delivered a staggering 212.6% one-year return, fueled by 33.4% revenue growth and a remarkable 85.8% ROIC. Ubiquiti’s gross margin is 43.4%, with a healthy 24.7% FCF margin. The company’s asset-light model and direct-to-customer sales drive exceptional capital efficiency.
Key Catalysts
- Network infrastructure expansion: Global demand for high-speed connectivity supports recurring revenue.
- Innovative product pipeline: Regular launches in wireless, switching, and security.
- Scalable business model: Low overhead and high operating leverage.
Risk Factors
- Competitive pressures: Intense rivalry in networking hardware.
- Debt levels: Higher debt-to-equity ratio 44.5% compared to peers.
- Customer concentration: Reliance on a subset of large clients.
Stock #3: ResMed Inc. (RMD)
| Metric | Value |
|---|---|
| Market Cap | $39.5B |
| Quality Rating | 7.7 |
| Intrinsic Value | $247.1 |
| 1Y Return | 13.3% |
| Revenue | $5,146.3M |
| Free Cash Flow | $1,658.7M |
| Revenue Growth | 13.2% |
| FCF margin | 32.2% |
| Gross margin | 59.4% |
| ROIC | 24.8% |
| Total Debt to Equity | 14.8% |
Investment Thesis
ResMed is a leader in sleep apnea and respiratory care devices, with a $39.5B market cap, a Quality Rating of 7.7, and an intrinsic value of $247.1. The company posted a 13.3% one-year return, 13.2% revenue growth, and industry-leading margins (59.4% gross, 32.2% FCF). ResMed’s ROIC is a robust 24.8%, and it maintains a conservative 14.8% debt-to-equity ratio.
Key Catalysts
- Aging population: Rising prevalence of sleep disorders drives device demand.
- Digital health adoption: Connected devices and cloud-based monitoring expand recurring revenue.
- Global reach: Strong presence in both developed and emerging markets.
Risk Factors
- Regulatory scrutiny: Medical device approvals and reimbursement changes.
- Competition: Rival products from Philips and others.
- Supply chain: Potential disruptions in component sourcing.
Stock #4: Nokia Oyj (NOK)
| Metric | Value |
|---|---|
| Market Cap | $30.4B |
| Quality Rating | 6.0 |
| Intrinsic Value | $7.6 |
| 1Y Return | 29.3% |
| Revenue | €19.2B |
| Free Cash Flow | €1,480.0M |
| Revenue Growth | (2.9%) |
| FCF margin | 7.7% |
| Gross margin | 73.3% |
| ROIC | 4.7% |
| Total Debt to Equity | 20.7% |
Investment Thesis
Nokia, a telecom infrastructure provider, has a $30.4B market cap, a Quality Rating of 6.0, and an intrinsic value of $7.6. The stock returned 29.3% over the past year, despite a slight revenue decline -2.9%. Nokia’s gross margin is high at 73.3%, but FCF margin is modest at 7.7%, with a low ROIC of 4.7%. Debt levels are manageable at 20.7%.
Key Catalysts
- 5G rollout: Global 5G infrastructure investments support equipment sales.
- Cost restructuring: Ongoing efficiency programs aim to improve profitability.
- Patent portfolio: Licensing revenue provides stability.
Risk Factors
- Revenue pressure: Slowing growth in core markets.
- Execution risk: Turnaround depends on successful cost management.
- Competitive landscape: Intense rivalry with Huawei, Ericsson.
Stock #5: First Solar, Inc. (FSLR)
| Metric | Value |
|---|---|
| Market Cap | $26.2B |
| Quality Rating | 6.7 |
| Intrinsic Value | $127.7 |
| 1Y Return | 21.0% |
| Revenue | $4,343.4M |
| Free Cash Flow | ($942.7M) |
| Revenue Growth | 15.4% |
| FCF margin | (21.7%) |
| Gross margin | 42.8% |
| ROIC | 13.7% |
| Total Debt to Equity | 12.5% |
Investment Thesis
First Solar is a leading solar panel manufacturer with a $26.2B market cap, a Quality Rating of 6.7, and an intrinsic value of $127.7. The stock returned 21.0% over the past year, with 15.4% revenue growth. Gross margin is 42.8%, but FCF is negative -$942.7M, reflecting heavy capital expenditures. ROIC is 13.7%, and debt is low at 12.5%.
Key Catalysts
- Renewable energy transition: Global push for decarbonization boosts demand.
- Technology leadership: Thin-film panels with competitive efficiency.
- Policy support: Government incentives in key markets.
Risk Factors
- Profitability challenges: Negative free cash flow amid expansion.
- Commodity pricing: Volatility in raw material costs.
- Competition: Chinese manufacturers dominate global supply.
Stock #6: Natera, Inc. (NTRA)
| Metric | Value |
|---|---|
| Market Cap | $24.5B |
| Quality Rating | 6.1 |
| Intrinsic Value | $78.2 |
| 1Y Return | 39.1% |
| Revenue | $1,964.2M |
| Free Cash Flow | $104.6M |
| Revenue Growth | 44.4% |
| FCF margin | 5.3% |
| Gross margin | 62.9% |
| ROIC | (48.3%) |
| Total Debt to Equity | 15.7% |
Investment Thesis
Natera specializes in genetic testing, with a $24.5B market cap, a Quality Rating of 6.1, and an intrinsic value of $78.2. The stock returned 39.1% over the past year, with 44.4% revenue growth. Gross margin is strong at 62.9%, but FCF margin is low at 5.3%, and ROIC is negative -48.3%. Debt is moderate at 15.7%.
Key Catalysts
- Genomic adoption: Increasing use of non-invasive prenatal and cancer testing.
- Pipeline expansion: New product launches in oncology and organ health.
- Insurance coverage: Broader reimbursement for genetic tests.
Risk Factors
- Profitability: Negative ROIC and thin FCF margins.
- Regulatory risk: Evolving guidelines for genetic testing.
- Competition: Rival firms with similar offerings.
Stock #7: NetApp, Inc. (NTAP)
| Metric | Value |
|---|---|
| Market Cap | $24.4B |
| Quality Rating | 7.0 |
| Intrinsic Value | $124.0 |
| 1Y Return | -2.7% |
| Revenue | $6,588.0M |
| Free Cash Flow | $1,658.0M |
| Revenue Growth | 3.3% |
| FCF margin | 25.2% |
| Gross margin | 70.0% |
| ROIC | 27.5% |
| Total Debt to Equity | 281.5% |
Investment Thesis
NetApp provides data storage solutions, with a $24.4B market cap, a Quality Rating of 7.0, and an intrinsic value of $124.0. The stock declined 2.7% over the past year, with modest 3.3% revenue growth. Gross margin is high at 70.0%, FCF margin is 25.2%, and ROIC is 27.5%. However, debt is elevated at 281.5%.
Key Catalysts
- Cloud transition: Hybrid cloud solutions drive recurring revenue.
- Efficiency focus: Cost controls support margins.
- Enterprise demand: Data growth underpins storage needs.
Risk Factors
- Debt levels: High leverage could constrain flexibility.
- Growth pace: Slower top-line expansion than peers.
- Competition: Intense rivalry in cloud storage.
Stock #8: Insulet Corporation (PODD)
| Metric | Value |
|---|---|
| Market Cap | $22.0B |
| Quality Rating | 7.6 |
| Intrinsic Value | $105.8 |
| 1Y Return | 35.8% |
| Revenue | $2,188.2M |
| Free Cash Flow | $392.6M |
| Revenue Growth | 16.8% |
| FCF margin | 17.9% |
| Gross margin | 76.3% |
| ROIC | 22.4% |
| Total Debt to Equity | 96.9% |
Investment Thesis
Insulet develops insulin delivery systems, with a $22.0B market cap, a Quality Rating of 7.6, and an intrinsic value of $105.8. The stock returned 35.8% over the past year, with 16.8% revenue growth. Gross margin is exceptional at 76.3%, FCF margin is 17.9%, and ROIC is 22.4%. Debt is higher at 96.9%.
Key Catalysts
- Diabetes prevalence: Rising global incidence supports device adoption.
- Product innovation: Next-gen pumps and digital integration.
- Reimbursement trends: Favorable coverage for insulin delivery.
Risk Factors
- Debt: Elevated leverage for a medtech firm.
- Competition: Rival insulin pump makers.
- Regulatory: Device approvals and safety monitoring.
Stock #9: ON Semiconductor Corporation (ON)
| Metric | Value |
|---|---|
| Market Cap | $20.9B |
| Quality Rating | 7.1 |
| Intrinsic Value | $77.4 |
| 1Y Return | -27.4% |
| Revenue | $6,398.8M |
| Free Cash Flow | $1,515.0M |
| Revenue Growth | (17.9%) |
| FCF margin | 23.7% |
| Gross margin | 37.6% |
| ROIC | 12.1% |
| Total Debt to Equity | 42.4% |
Investment Thesis
ON Semiconductor is a chipmaker with a $20.9B market cap, a Quality Rating of 7.1, and an intrinsic value of $77.4. The stock declined 27.4% over the past year, with a 17.9% revenue drop. Gross margin is 37.6%, FCF margin is 23.7%, and ROIC is 12.1%. Debt is moderate at 42.4%.
Key Catalysts
- Automotive and industrial: Exposure to electric vehicles and factory automation.
- Efficiency gains: Cost reductions amid industry downturn.
- Long-term contracts: Stability from design wins.
Risk Factors
- Cyclicality: Semiconductor industry volatility.
- Revenue pressure: Recent sales decline.
- Competition: Crowded field in analog chips.
Stock #10: Waters Corporation (WAT)
| Metric | Value |
|---|---|
| Market Cap | $19.8B |
| Quality Rating | 6.3 |
| Intrinsic Value | $220.9 |
| 1Y Return | -7.7% |
| Revenue | $3,046.1M |
| Free Cash Flow | $619.4M |
| Revenue Growth | 5.9% |
| FCF margin | 20.3% |
| Gross margin | 58.6% |
| ROIC | 19.0% |
| Total Debt to Equity | 71.2% |
Investment Thesis
Waters provides analytical instruments, with a $19.8B market cap, a Quality Rating of 6.3, and an intrinsic value of $220.9. The stock declined 7.7% over the past year, with 5.9% revenue growth. Gross margin is 58.6%, FCF margin is 20.3%, and ROIC is 19.0%. Debt is elevated at 71.2%.
Key Catalysts
- Pharma and biotech: R&D spending supports instrument demand.
- Service revenue: Recurring income from maintenance and consumables.
- Geographic expansion: Growth in emerging markets.
Risk Factors
- Debt: Higher leverage than peers.
- End-market concentration: Reliance on life sciences.
- Competition: Rival analytical instrument makers.
Portfolio Diversification Insights
This watchlist spans semiconductors (ASML, ON), networking (Ubiquiti), healthcare (ResMed, Natera, Insulet), renewable energy (First Solar), telecom (Nokia), data storage (NetApp), and analytical instruments (Waters). Such sectoral diversity helps mitigate concentration risk while capturing growth across multiple megatrends: digital transformation, healthcare innovation, and energy transition. Investors can tailor allocations based on risk tolerance, with higher-quality, lower-debt names like ASML and ResMed offering stability, while higher-growth, higher-risk picks like Ubiquiti and Natera provide upside potential.
Market Timing & Entry Strategies
Given the varied performance and valuation profiles, a staggered entry approach is prudent. For stocks trading near or below intrinsic value (e.g., Nokia, ON Semiconductor), consider gradual accumulation on weakness. For high-momentum names (e.g., Ubiquiti, Natera), monitor for pullbacks to historical support levels. For stable compounders (e.g., ASML, ResMed), dollar-cost averaging can smooth entry points. Always align position sizing with individual risk profiles and portfolio goals.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- 10 Best Climatetech for October 2025
- 10 Best Biotech for October 2025
- 10 Best Agritech for October 2025
- 10 Best Automotivetech for October 2025
- 10 Best Agritech for October 2025
FAQ Section
Q1: How were these stocks selected?
Stocks were screened using ValueSense’s proprietary quality and intrinsic value metrics, emphasizing financial health, growth potential, and reasonable valuation. Only companies with clear catalysts and manageable risks were included.
Q2: What's the best stock from this list?
There is no single “best” stock—each offers distinct risk/reward profiles. ASML and ResMed stand out for quality and stability, while Ubiquiti and Natera offer higher growth potential.
Q3: Should I buy all these stocks or diversify?
Diversification is key. This list is designed to provide a balanced exposure across sectors. Consider your own risk tolerance and investment goals when building a portfolio.
Q4: What are the biggest risks with these picks?
Risks include industry cyclicality, competitive pressures, debt levels, and execution challenges. Review each stock’s risk factors and monitor market conditions.
Q5: When is the best time to invest in these stocks?
Timing depends on market conditions and individual stock valuations. A disciplined, long-term approach—focusing on intrinsic value and quality—is generally more effective than trying to time the market.
Note: All data and analysis are based exclusively on the provided ValueSense screenshots. For the latest prices, detailed financials, and updated research, visit ValueSense. This content is for educational purposes only and not investment advice. Always conduct your own due diligence.